1-[4-(4-Iodophenoxy)butyl]pyrrolidine | 415934-62-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[4-(4-Iodophenoxy)butyl]pyrrolidine
• CAS: 415934-62-2
• 化学式: C₁₄H₂₀INO
• 分子量: 345.223
• InChiKey: YNKBXBKGVGDJHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-双(恶唑-5-基)苯 、 1-[4-(4-Iodophenoxy)butyl]pyrrolidine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三苯基膦 、 silver carbonate 作用下， 以 水 为溶剂， 反应 36.0h， 生成 1,3-bis(2-(4-(4-(pyrrolidin-1-yl)butoxy)phenyl)oxazol-5-yl)benzene
  参考文献：
  名称：

  Sequences in the HSP90 promoter form G-quadruplex structures with selectivity for disubstituted phenyl bis-oxazole derivatives

  摘要：

  The HSP90 protein is an important target in cancer. We report here that stable quadruplex DNAs can be formed from a promoter sequence in the HSP90 gene, on the basis of melting, circular and NMR studies, and show that these can be selectively targeted by non-macrocyclic quadruplex-stabilizing phenyl bis-oxazole derivatives. These do not bind significantly to duplex DNA and show low stabilization of the human telomeric quadruplex. These results suggest an approach to targeting HSP90 at the DNA level. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.065

文献信息

• [EN] ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES<br/>[FR] ADMINISTRATION DE DÉRIVÉS DE CARBOLINE UTILISÉS DANS LE TRAITEMENT DU CANCER ET AUTRES MALADIES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2008127714A1

  公开（公告）日：2008-10-23

  [EN] In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject.
  [FR] La présente invention concerne des composés utilisés dans un procédé ou dans la fabrication d'un médicament visant à inhiber de manière post-transcriptionnelle l'expression du facteur de croissance de l'endothélium vasculaire (VEGF) chez un sujet nécessitant un tel traitement, ledit procédé consistant à inhiber la traduction de l'ARNm du facteur de croissance VEGF en administrant ce médicament par voie orale audit sujet à raison d'une, deux ou trois fois par jour.
• Sequences in the HSP90 promoter form G-quadruplex structures with selectivity for disubstituted phenyl bis-oxazole derivatives
  作者：Stephan A. Ohnmacht、Marialuisa Micco、Vanessa Petrucci、Alan K. Todd、Anthony P. Reszka、Mekala Gunaratnam、Marta A. Carvalho、Mire Zloh、Stephen Neidle

  DOI：10.1016/j.bmcl.2012.07.065

  日期：2012.9

  The HSP90 protein is an important target in cancer. We report here that stable quadruplex DNAs can be formed from a promoter sequence in the HSP90 gene, on the basis of melting, circular and NMR studies, and show that these can be selectively targeted by non-macrocyclic quadruplex-stabilizing phenyl bis-oxazole derivatives. These do not bind significantly to duplex DNA and show low stabilization of the human telomeric quadruplex. These results suggest an approach to targeting HSP90 at the DNA level. (C) 2012 Elsevier Ltd. All rights reserved.